Sector News

ConvaTec to bolster senior leadership

December 5, 2017
Life sciences

Medical product and technology company ConvaTec Group PLC said on Monday it has made several senior appointments as a result of changes to its organisational structure.

From January 1, 2018 the group’s four franchises will he headed by Franchise Presidents who will report directly to the Chief Executive Officer, and will responsible for the development and delivery of its strategic plans across all its target markets, as well as marketing and research & development within their franchises.

Peter Byloos will be appointed as head of Advanced Wound Care. He will be joining from European investment company Gimv, where he is partner for healthcare for nearly three years since the start of 2015.

Erik Zimmer will continue as vice president & general manager of Ostomy Care, with an appointment of a president for the franchise to be made in due course.

ConvaTec will promote current Interim President of Europe, Middle East & Africa Frank Gehres as president of Continence and Critical Care, with Mads Haugaard reporting to him as vice president & general manager.

Gehres will be replaced as president of Europe, Middle East & Africa by Kjersti Grimsrud, who will be joining from rapid point-of-care diagnostics tests manufacturer Alere Inc, where she was president of Europe & Middle East and president International for three and a half years since 2014.

John Lindskog will continue as president with responsibility over the Infusion Devices franchise.

In addition, ConvaTec will appoint Sean McGrath as executive vice president of global human resources, joining from the World Bank Group where he was vice president of human resources for five years since 2012. He will be replacing Marc Reuss, who has held the role for two years since 2015.

Also, President of Global Franchises and Innovation Symeria Hudson, will be leaving with effect at the end of 2017, after nearly two years in the role since March 2016.

“These important changes to our organisation will drive a greater focus on the leadership of our Franchises and on their performance as business units of ConvaTec, as well as providing better leverage of our strong new product pipeline. I am confident that this new structure will enable us to drive increased value from our leading market positions across each of the businesses,” said Chief Executive Officer Paul Moraviec.

Shares in ConvaTec were up 1.2% at 201.90 pence on Monday.

By Dayo Laniyan

Source: Alliance News

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach